Oestrogen-dependent expression of the SM2 smooth muscle-type myosin isoform in rabbit myometrium.
Ovarectomized rabbits displayed a decreased SM1 to SM2 ratio of smooth muscle-type myosin heavy chain isoforms compared to unoperated, virgin females which was reversed after 17beta-oestradiol administration to a value similar to that of control animals. When this steroid was given to sexually immature animals or to adult virgin rabbits, SM2 expression was not induced, as also happened with proliferating myometrial smooth muscle cells grown in vitro. In growing rabbit, the 17beta-oestradiol administration induced the formation of the circular and the longitudinal muscle layers, characteristics of sexually competent females. The SM2 isoform was up-regulated during postnatal development and the SM1 to SM2 ratio changed during pregnancy and post-partum period but not with human gonadotropin treatment which increases the level of circulating progesterone. Immunofluorescence staining of adult myometrium with anti-SM2 antibody indicated that this isoform is localized to the longitudinal layer exclusively and, in contrast to the circular layer, its expression was independent of oestrogen level. Difference in oestrogen sensitivity between the two layers was also detected for the expression of the intermediate filament protein vimentin and the thin filament protein calponin. Changes of SM2 expression in the myometrium correlated with variations in the oestrogen receptor density as also confirmed by decreased SM2 content/oestrogen receptor density in the circular layer when ovarectomized females were treated with the oestrogen antagonist ICI 182,780. Our results indicate that: (1) a specific distribution of myosin heavy chain exists within rabbit myometrium, and (2) SM2 myosin expression in this smooth muscle is under oestrogen control.
Capriani
A
A
Department of Biomedical Sciences, University of Padua, Italy.
Chiavegato
A
A
Franch
R
R
Azzarello
G
G
Vinante
O
O
Sartore
S
S
D000818:Animals; D002135:Calcium-Binding Proteins / Q000032:analysis; D004958:Estradiol / Q000031:analogs & derivatives / Q000494:pharmacology; D004965:Estrogen Antagonists / Q000494:pharmacology; D004967:Estrogens / Q000097:blood* / Q000494:pharmacology; D005260:Female; D000077267:Fulvestrant; D007527:Isoenzymes / Q000032:analysis*; D008840:Microfilament Proteins; D009124:Muscle Proteins / Q000032:analysis; D009130:Muscle, Smooth / Q000737:chemistry* / Q000187:drug effects / Q000378:metabolism; D009215:Myometrium / Q000737:chemistry*; D018995:Myosin Heavy Chains / Q000032:analysis*; D010052:Ovariectomy; D011247:Pregnancy; D011817:Rabbits; D011960:Receptors, Estrogen / Q000032:analysis; D014746:Vimentin / Q000032:analysis; D000096985:Calponins
D002135:Calcium-Binding Proteins; D004958:Estradiol; D004965:Estrogen Antagonists; D004967:Estrogens; D000077267:Fulvestrant; D007527:Isoenzymes; D008840:Microfilament Proteins; D009124:Muscle Proteins; D018995:Myosin Heavy Chains; D011960:Receptors, Estrogen; D014746:Vimentin; D000096985:Calponins